Late-stage biotech OncoSec Medical (ONCS) has announced that it has entered into purchase agreements for an aggregate 4,608,589 of its shares at an offering …
Are penny stocks a must-have or a must-avoid? Well, that depends on who you ask.
Some investors might love biotech stocks for their lottery ticket-like returns when a company strikes medical gold. A lottery ticket, however, costs only …
H.C.
It’s a very rewarding trading day for investors in OncoSec Medical Inc (NASDAQ:ONCS) with shares up over 180%, making the stock Wall Street’s …
OncoSec Medical Inc (NASDAQ:ONCS) shares are rising almost 8% ahead of the biotech firm’s immune data presentation tomorrow at the American Association for …
OncoSec Medical Inc (NASDAQ:ONCS) announced financial results for the fourth quarter and fiscal year ended July 31, 2016. “During the fourth quarter, we continued …
OncoSec Medical Inc (NASDAQ:ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced Sharron Gargosky, PhD, has been appointed to Chief Clinical and Regulatory …
OncoSec Medical Inc (NASDAQ:ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today presented preliminary findings from OMS-I130, a Phase II clinical trial of ImmunoPulse™ …
OncoSec Medical Inc (NASDAQ:ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced that it has closed its previously announced at-the-market registered direct offering …